This trial is evaluating whether Human Acellular Vessel (HAV) will improve 1 primary outcome and 14 secondary outcomes in patients with Vascular System Injuries. Measurement will happen over the course of 36 months.
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. Human Acellular Vessel (HAV) is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Traumatic injuries to the vascular system can lead to serious complications, and include vascular trauma, thrombosis (blood clots), embolism, and hematoma (bleeding inside the blood vessel). Patients with vascular system injuries are often at increased risk for secondary injuries as well.
This article presents case histories of patients with vascular system injuries. The underlying etiology in most cases is unknown. We suggest to think about the vascular system injuries as a consequence of an injury to a blood vessel, not as a cause. In the last decades, the vascular system injuries have become a serious clinical problem that can be prevented by applying good standards of care. This article is written with the aim of facilitating such standards of care.
About 3.6 million people have been treated for vascular system injuries in the United States in 2011. This number may be underestimated because physicians who treat patients with vascular system injuries often treat only symptoms and neglect their actual injuries. It is important for health planners to incorporate vascular injuries into U.S. trauma allocation priorities.
Data from a recent study of this study suggest that in addition to cigarette smoking, other environmental factors are involved in the development of vascular system injuries in haemodialysis patients. Therefore, it may be necessary to reconsider the way we manage vascular system injuries in haemodialysis patients.
answer: The long-term outcome in patients with extensive vascular injuries is good. The complication rate is too high in this population to make this a viable option. Better treatment strategies and strategies to prevent additional complications should be considered.
Findings from a recent study shows the treatment for vascular system injuries has changed little over the last few decades. Most patients are seen in the surgery clinics of both teaching and teaching institutions and undergo surgery of varying complexity. The use of CT has a major effect on the management of vascular system injuries. More recently, it continues to be used for other applications in the treatment of vascular system injuries. There is discussion of the use of endovascular therapies. There is a need for a better understanding of the causes and treatment for vascular injuries. The use of endovascular treatment and the expanding use of CT imaging should reduce the treatment delays and hospitalization times.
Clinicians should consider potential trial benefits, but potential harms must be considered. All clinicians can participate in both clinical and clinical research, while clinicians specializing in vascular systems injuries may wish to consider participating in a clinical trial of a new treatment.
Compared to the HAV therapy alone, human acellular vessel treatment significantly reduced vessel proliferation, fibrosis, and MMP-9 production, and effectively improved survival, suggesting that human acellular vessel can improve the viability of animal's tissues.
The findings from the study suggest that VCs may be associated with an increased risk of arterial injury. The findings of the present study point to the necessity of a detailed history of previous injuries in VC families, of vascular system injuries may be causally related to VCs, both of which must be taken into consideration prior to initiation of therapy, especially in patients with renal insufficiency.
Although many of the studies show a positive effect with hAV application, no long- term studies are yet available. No studies have been performed on the use of hAV in acute or chronic situations. Nevertheless, results are awaited and further studies may be justified. hAV can induce a favorable immune reaction. For certain vascular applications it cannot be excluded, that the hAV has adjuvant properties.
The findings are consistent with an increased re-endothelialization rate attributable to exposure to Hav, with corresponding improvements in the preservation of endothelial function. Hav is also superior to the controls for improving hemodynamic parameters as well as arterial wall properties. In a recent study, findings provide evidence of an improvement in the remodeling process associated with endothelial degeneration and thus the remodeling of vascular vessels following injury.
Because arteriovenous shunts do not cause severe symptoms in patients, other possible ways of creating arterial substitutes are being investigated. Recent findings found that hAV shows a potential for use in patients who need a temporary bypass grafting or with limb defects requiring temporary arterial conduits.